Trial · NCT07902258
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
NCT07902258, Phase 2, Not yet recruiting, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC. Trials, record NCT07902258. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902258
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
- NCT number
- NCT07902258
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant Therapy
- Interventions
- Nivolumab
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of single-dose neoadjuvant Nivolumab for resectable HCC | approximately within 8 weeks after enrollment | Feasibility is evaluated by whether curative-intent surgery could be performed without delay exceeding \>14 days from the planned date. |
| Primary | 56-week event-free survival | 56 weeks from the date of neoadjuvant Nivolumab intravenous infusion | Prespecified events including: delay of curative-intent surgery by exceeding \>14 days attributable to neoadjuvant nivolumab, surgical cancellation due to any treatment-related adverse events or clinical disease progression, postoperative disease recurrence, or death from any cause. |
| Secondary | To assess the safety and pathological response of single-dose neoadjuvant Nivolumab for resectable HCC | 56 weeks from the date of neoadjuvant Nivolumab intravenous infusion | Adverse events, pathological response |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902258
GET https://conductscience.org/api/trials/v1/NCT07902258/registered